Toxicity and Surface Modification of Dendrimers: A Critical Review

Kharwade, Rohini; Badole, Payal; Mahajan, Nilesh; More, Sachin

doi:10.2174/1567201818666211021160441

Cited by 16 publications

(5 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potency of viral inhibition reported in these studies was not as significant as ours. Moreover, LNPs and positive charge dendrimer have been found to be capable of inducing immune or cell toxicity (Kedmi et al , 2010 ; Kharwade et al , 2021 ), which might limit the safety window for dosing. These properties also increase the difficulty and cost of industrial production.…”

Section: Discussionmentioning

confidence: 99%

A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant

Chang¹,

Yang

Chen³

et al. 2022

EMBO Mol Med

View full text Add to dashboard Cite

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on the long-term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC 50 in vitro. Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18-hACE2transgenic mice, accompanied by a significant prevention of virusassociated extensive pulmonary alveolar damage, vascular thrombi, and immune cell infiltrations. Our data suggest that C6G25S provides an alternative and effective approach to combating the COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant

Chang¹,

Yang

Chen³

et al. 2022

EMBO Mol Med

View full text Add to dashboard Cite

show abstract

“…The cytotoxic activity, hemolytic properties, cellular uptake, or ability to transport and release different cargo compounds of many dendrimers have already been studied in vitro [ 9 , 71 ]. However, studies in isolated groups of cells do not accurately model the difficulties nanoparticles must overcome to reach their targets in vivo.…”

Section: In Vivo Use Of Dendrimersmentioning

confidence: 99%

In Vivo Applications of Dendrimers: A Step toward the Future of Nanoparticle-Mediated Therapeutics

Sztandera,

Rodríguez-García,

Ceña

2024

Pharmaceutics

View full text Add to dashboard Cite

Over the last few years, the development of nanotechnology has allowed for the synthesis of many different nanostructures with controlled sizes, shapes, and chemical properties, with dendrimers being the best-characterized of them. In this review, we present a succinct view of the structure and the synthetic procedures used for dendrimer synthesis, as well as the cellular uptake mechanisms used by these nanoparticles to gain access to the cell. In addition, the manuscript reviews the reported in vivo applications of dendrimers as drug carriers for drugs used in the treatment of cancer, neurodegenerative diseases, infections, and ocular diseases. The dendrimer-based formulations that have reached different phases of clinical trials, including safety and pharmacokinetic studies, or as delivery agents for therapeutic compounds are also presented. The continuous development of nanotechnology which makes it possible to produce increasingly sophisticated and complex dendrimers indicates that this fascinating family of nanoparticles has a wide potential in the pharmaceutical industry, especially for applications in drug delivery systems, and that the number of dendrimer-based compounds entering clinical trials will markedly increase during the coming years.

show abstract

“…However, there are specific concerns that require further attention. Firstly, unmodified PAMAM materials with positively charged surfaces are generally considered toxic [74]. Secondly, smaller PAMAMs can be easily eliminated by the kidneys; in contrast, larger ones tend to be recognized by the reticuloendothelial system (RES) [75].…”

Section: Polyamidoamine Dendrimersmentioning

confidence: 99%

Research Progress of Drug Delivery Systems Targeting the Kidneys

Huang,

Ye,

Chen

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Chronic kidney disease (CKD) affects more than 10% of the global population, and its incidence is increasing, partially due to an increase in the prevalence of disease risk factors. Acute kidney injury (AKI) is an independent risk factor for CKD and end-stage renal disease (ESRD). The pathogenic mechanisms of CKD provide several potential targets for its treatment. However, due to off-target effects, conventional drugs for CKD typically require high doses to achieve adequate therapeutic effects, leading to long-term organ toxicity. Therefore, ideal treatments that completely cure the different types of kidney disease are rarely available. Several approaches for the drug targeting of the kidneys have been explored in drug delivery system research. Nanotechnology-based drug delivery systems have multiple merits, including good biocompatibility, suitable degradability, the ability to target lesion sites, and fewer non-specific systemic effects. In this review, the development, potential, and limitations of low-molecular-weight protein–lysozymes, polymer nanomaterials, and lipid-based nanocarriers as drug delivery platforms for treating AKI and CKD are summarized.

show abstract

Toxicity and Surface Modification of Dendrimers: A Critical Review

Cited by 16 publications

References 117 publications

A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant

A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant

In Vivo Applications of Dendrimers: A Step toward the Future of Nanoparticle-Mediated Therapeutics

Research Progress of Drug Delivery Systems Targeting the Kidneys

Contact Info

Product

Resources

About